Olaparib
Cat. No.：YN280012
CAS No. ：763113-22-0
| 产品名称: | Olaparib |
| CAS No.: | 763113-22-0 |
| Chemical Name: | 4-[[3-[[4-(cyclopropylcarbonyl)-1-piperazinyl]carbonyl]-4-fluorophenyl]methyl]-1(2H)-phthalazinone |
| Synonyms: | 奥拉帕尼; AZD2281; KU0059436 |
| 分子量: | 434.46 |
| 分子式: | C₂₄H₂₃FN₄O₃ |
| SMILES: | O=C(C1=CC(CC(C2=C3C=CC=C2)=NNC3=O)=CC=C1F)N4CCN(C(C5CC5)=O)CC4 |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Olaparib (AZD2281; KU0059436) 是一种口服有效的PARP抑制剂，抑制PARP-1和PARP-2的IC50分别为 5 和 1 nM。Olaparib 是一种自噬 (autophagy) 和线粒体自噬 (mitophagy) 激活剂。 |
| IC50和靶点: | [{name:"PARP-2:1 nM (IC50)"},{name: "PARP-1:5 nM (IC50)"},{name: "tankyrase-1:1.5 μM (IC50)'}, 'Autophagy', 'Mitophagy'] |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Rowe, B.P., and Glazer, P.M.Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanismsBreast Cancer Res.12(2),1-11(2010)
Davar, D., Beumer, J.H., Hamieh, L., et al.Role of PARP inhibitors in cancer biology and therapyCurr. Med. Chem.19(23),3907-3921(2012)
Menear, K.A., Adcock, C., Boulter, R., et al.4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A novel bioavailable inhibitor of Poly(ADP-ribose) polymerase-1J. Med. Chem.51(20),6581-6591(2008)
Yuan, Y., Liao, Y.M., Hsueh, C.T., et al.Novel targeted therapeutics: Inhibitors of MDM2, ALK and PARPJ. Hematol. Oncol.4(16),1-14(2011)
Plummer, R.Poly(ADP-ribose) polymerase inhibition: A new direction for BRCA and triple-negative breast cancer?Breast Cancer Res.13(4),1-6(2011)
Javle, M., and Curtin, N.J.The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapyTher. Adv. Med. Oncol.3(6),257-267(2011)
